Bajaj HealthCare
352.55
-3.90(-1.09%)
Market Cap₹1,113.47 Cr
PE Ratio22.60
IndustryHealthcare
Company Performance:
1D-1.09%
1M-10.02%
6M-21.54%
1Y-48.84%
5Y-2.87%
View Company Insightsright
More news about Bajaj HealthCare
16Jan 26
Bajaj Healthcare Q3FY26 Results: Revenue Surges 31% YoY to ₹16,122 Crores, Board Approves Leadership Reappointments
Bajaj Healthcare Limited reported impressive Q3FY26 results with revenue from operations growing 31.30% year-on-year to ₹16,122.27 crores. Net profit from continuing operations increased 7.60% to ₹1,610.09 crores, while nine-month revenue reached ₹45,797.39 crores, up 18.00% from the previous year. The Board approved reappointment of key executive directors including Chairman & Managing Director Sajankumar Rameshwarlal Bajaj and Managing Director Anil Champalal Jain for three-year terms starting April 2026, subject to shareholder approval.
 no imag found
13Jan 26
Bajaj Healthcare Appoints Umeshkumar Bhavsar as Independent Director for Five-Year Term
Bajaj Healthcare Limited has appointed Mr. Umeshkumar Laxmidas Bhavsar as Additional Director (Non-Executive Independent Director) effective January 13, 2026, for a five-year term until January 12, 2031. The qualified Chartered Accountant brings over 35 years of experience across real estate, financial services, retail, manufacturing, and consulting sectors, having served in key financial leadership roles at Ajmera Realty & Infra India Limited for more than 15 years. The appointment, subject to shareholder approval, meets all regulatory compliance requirements under the Companies Act, 2013, and SEBI regulations.
 no imag found
05Jan 26
Bajaj Healthcare Appoints Mrs. Purnima Dhanraj Amin as Independent Director for Five-Year Term
Bajaj Healthcare Limited has appointed Mrs. Purnima Dhanraj Amin as Additional Director (Non-Executive Independent Director) for a five-year term from January 05, 2026 to January 04, 2031, subject to shareholder approval. Mrs. Amin is a Professor of Pharmacy at ICT Mumbai with over 32 years of academic experience and expertise in drug delivery systems. She has confirmed meeting independence criteria under applicable regulations and is not related to any existing company directors.
 no imag found
31Dec 25
Bajaj Healthcare Receives CDSCO Approval for Suvorexant Clinical Trial on Dec 31
Bajaj Healthcare Limited has secured regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) on December 31, 2025, to conduct clinical trials and bioequivalence study for Suvorexant tablets. This milestone enables the company to advance its research in sleep disorder treatments and demonstrates adherence to regulatory standards in pharmaceutical development.
 no imag found
13Dec 25
Bajaj Healthcare Promoter Anil Champala Jain Acquires 2,000 Additional Equity Shares
Anil Champala Jain, Managing Director of Bajaj Healthcare Limited, acquired 2,000 equity shares through open market transactions on December 10, 2025. This acquisition increased his total shareholding from 60.69% to 60.76%. The transaction was disclosed in compliance with SEBI regulations.
 no imag found
08Dec 25
Bajaj Healthcare Unveils Investor Presentation, Showcasing Strong Financial Position and Diverse Operations
Bajaj Healthcare Limited (BHL) has released an investor presentation for its upcoming analyst and institutional investor meeting on December 08-09, 2025. The presentation outlines BHL's diverse operations across API manufacturing, formulations, alkaloid processing, and CDMO business, with a global reach to over 60 countries. Financial highlights include an 8.87% increase in total assets to ₹833.00 crore, a 67.46% rise in total equity to ₹466.20 crore, and a 20% growth in current assets to ₹485.40 crore. The meeting is expected to focus on performance across business verticals, global market presence, CDMO partnerships, financial strategies, and alkaloid processing operations.
 no imag found
17Oct 25
Bajaj Healthcare Reports Q2 FY26 Revenue of ₹1,470.49 Crore, PAT at ₹1,110.92 Crore
Bajaj Healthcare Limited announced strong Q2 FY26 results with revenue from operations increasing 13.04% YoY to ₹1,470.49 crore. Profit After Tax rose 17.37% to ₹1,110.92 crore. For H1 FY26, revenue surged 44.50% to ₹2,967.51 crore, with PAT up 38.24% to ₹2,294.29 crore. The company's EPS for Q2 FY26 improved to ₹3.53. Bajaj Healthcare also reported acquiring Genrx Pharmaceuticals Private Limited for ₹1,085 lakhs in April 2025.
 no imag found
04Oct 25
Bajaj Healthcare Secures Approval for Phase III Trials of Insomnia Drug Suvorexant
Bajaj Healthcare Limited (BHL) has received approval from the Subject Expert Committee of CDSCO to conduct Phase III clinical trials for Suvorexant Tablets in India. Suvorexant, a prescription medication for treating insomnia in adults, will be tested in 5 mg, 10 mg, 15 mg, and 20 mg strengths. BHL is the first company in India to receive this regulatory clearance for Suvorexant. The trials aim to assess the drug's efficacy, safety, and tolerability before seeking marketing authorization. BHL shares closed at ₹482.60, up 0.62% following the news.
 no imag found
11Sept 25
Bajaj Healthcare Announces Record Date for Final Dividend of FY 2024-25
Bajaj Healthcare Limited has announced September 19, 2025, as the record date for the final dividend of ₹1.00 per equity share (20%) for FY 2024-25. The dividend is subject to approval at the upcoming Annual General Meeting. Shareholders holding equity shares on the record date will be eligible for the dividend payment. The announcement complies with SEBI regulations and has been communicated to the BSE and NSE.
 no imag found
18Aug 25
Bajaj Healthcare Appoints Sandeep Shah as Additional Non-Executive Director
Bajaj Healthcare's Board of Directors has appointed Sandeep Shah as an Additional Director in the Non-Executive Non-Independent category, effective August 18, 2025. Shah, a commerce graduate with over 23 years of experience in Registrar and Share Transfer services, has worked with organizations like Karvy Consultants Private Limited and Par Computer Sciences (International) Limited. He also has more than 16 years of experience in Company Secretarial work with a PCS firm. The appointment is subject to shareholder approval.
 no imag found
28Jul 25
Bajaj Healthcare Reports Strong Q1 Results, Projects Robust Growth
Bajaj Healthcare Limited reported impressive Q1 financial results with revenue from operations increasing by 12.5% year-on-year to ₹148.84 crore. The company's API export business surged by 68.4%, while the formulations segment grew by 41.1%. Profit for the period rose by 65.9% to ₹11.83 crore. The company received new regulatory approvals, advanced its CDMO operations, and made progress in pipeline development. Bajaj Healthcare's export contribution increased to 35% of total revenue, up from 23% in the same quarter last year.
 no imag found
28Jul 25
Bajaj Healthcare Reports 66% Surge in Q1 Net Profit Amid Revenue Growth
Bajaj Healthcare announced its Q1 FY2026 results, reporting a 66% increase in net profit to ₹118.00 crore. Revenue grew by 12.6% to ₹1,488.00 crore. However, EBITDA remained flat at ₹245.00 crore, with margins compressing to 16.47% from 18.53% year-over-year. The Board of Directors approved these unaudited standalone financial results on July 28, 2025, after a review by statutory auditors Walker Chandiok & Co. LLP.
 no imag found
27May 25
Bajaj Healthcare Swings to Profit in Q4, Announces Dividend
Bajaj Healthcare Ltd. reported a significant turnaround in Q4, posting a net profit of ₹111.80 crore compared to a loss of ₹299.20 crore in the previous year. Revenue increased to ₹154.00 crore, up 14.93% year-over-year. The company's board recommended a final dividend of ₹1.00 per equity share. Despite the strong yearly recovery, there was a slight decrease in profit from ₹117.20 crore in the previous quarter.
 no imag found
26May 25
Bajaj Healthcare Reports Q4 Profit Turnaround and Announces Dividend
Bajaj Healthcare Limited's Q4 results show a significant improvement, with revenue increasing by 14.93% to ₹154.00 crore. The company returned to profitability with a net profit of ₹11.18 crore, compared to a loss of ₹29.92 crore in the same quarter last year. Despite EBITDA declining to ₹11.76 crore and margins contracting to 7.61%, the board recommended a final dividend of ₹1.00 per equity share.
 no imag found
10Apr 25
Bajaj Healthcare Strengthens Financial Leadership with Appointment of Rohan Parekh as CFO
Bajaj Healthcare Limited has appointed Mr. Rohan Parekh as the new Chief Financial Officer (CFO) and Key Managerial Personnel, effective April 16, 2025. Mr. Parekh, a qualified chartered accountant with over 13 years of experience, brings expertise in corporate strategy, financial planning, and treasury management. Additionally, the company has granted 2,500 stock options to employees under its 2024 ESOP plan, with an exercise price of Rs. 5.00 per option.
 no imag found
08Apr 25
Bajaj Healthcare Expands with Genrx Pharmaceuticals Acquisition, Considers Bonus Shares
Bajaj Healthcare Limited has acquired Genrx Pharmaceuticals Private Limited for ₹10.85 crore in an all-cash deal, gaining 100% control. The acquisition, completed on April 4, 2025, aims to expand Bajaj Healthcare's manufacturing capabilities. Genrx Pharmaceuticals is a WHO-GMP certified manufacturer specializing in allopathic formulations, nutraceuticals, and natural products. The integration is expected to take 3-6 months, pending regulatory approvals. Additionally, Bajaj Healthcare's board will meet on April 16 to consider issuing bonus shares.
 no imag found
07Apr 25
Bajaj Healthcare Expands Manufacturing Capabilities with ₹10.85 Crore Acquisition of Genrx Pharmaceuticals
Bajaj Healthcare Limited (BHL) has acquired Genrx Pharmaceuticals Private Limited for ₹10.85 crore in cash, gaining 100% control. Genrx, a WHO-GMP certified manufacturer, specializes in allopathic formulations, nutraceuticals, and natural products. The acquisition expands BHL's manufacturing portfolio, strengthening its position in the pharmaceutical sector. The deal is expected to close in 3-6 months, pending regulatory approvals.
 no imag found
03Apr 25
Bajaj Healthcare CFO Dayashankar Patel Resigns, Effective April 15
Bajaj Healthcare Limited (BHL) announced the resignation of CFO Dayashankar Patel, effective April 15, 2025, citing personal reasons. The company appreciated his services and confirmed no material reasons for the resignation beyond those stated. The announcement complies with SEBI regulations, and BHL is expected to manage the transition in financial leadership.
 no imag found
02Apr 25
Bajaj Healthcare CFO Dayashankar Patel Steps Down, Citing Personal Reasons
Bajaj Healthcare Limited announced that its Chief Financial Officer (CFO), Dayashankar Patel, has resigned due to personal reasons. Patel will be relieved from his duties as CFO and Key Managerial Personnel after April 15, 2025. The company expressed appreciation for Patel's services and confirmed no material reasons for the resignation beyond those stated. The announcement was made on April 2, 2025, allowing for a brief transition period. Bajaj Healthcare has complied with SEBI regulations by disclosing the change to relevant stock exchanges. No successor has been announced yet.
 no imag found
Bajaj HealthCare
352.55
-3.90
(-1.09%)
1 Year Returns:-48.84%
Industry Peers
Sun Pharmaceutical
1,724.40
(+0.64%)
Divis Laboratories
6,291.00
(-0.10%)
Torrent Pharmaceuticals
4,241.70
(+0.36%)
Cipla
1,341.10
(+0.92%)
Dr Reddys Laboratories
1,280.40
(-0.15%)
Lupin
2,219.40
(-0.42%)
Zydus Life Science
900.75
(-0.18%)
Mankind Pharma
2,024.30
(-0.75%)
Aurobindo Pharma
1,158.80
(-1.08%)
Alkem Laboratories
5,392.00
(+0.28%)